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Background: Compared with warfarin, apixaban has been shown to reduce stroke, systemic embolism, mortality and major bleeding. Amiodarone 
may lead to poor INR control and excess embolic and bleeding events when used with warfarin. Interactions between apixaban and amiodarone on 
clinical outcomes have not been explored. 
methods: The Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial included 18,201 patients 
randomized to apixaban 5mg twice daily or warfarin (target INR 2-3). This analysis explores outcomes in patients on and off amiodarone. Endpoints 
were summarized using rates/100 patient years of follow-up. The Cox regression model was used to derive hazard ratios comparing apixaban vs. 
warfarin and test the interaction between randomized treatment and amiodarone.
results: From the overall population, 2,051 (11%) patients received amiodarone at randomization including 1,009 patients assigned to apixaban 
and 1,042 assigned to warfarin. Patients on amiodarone were younger (median 68 vs. 70 years) and had lower CHADS2 score (mean 2.0 vs. 2.1). 
Patients assigned to warfarin who were on amiodarone had a lower mean time in therapeutic range (TTR) when compared with those who were not 
on amiodarone (56.5% vs. 63%, p < 0.0001). Outcomes are shown in the table.
conclusions: Despite a lower TTR with warfarin and amiodarone, the efficacy and safety of apixaban versus warfarin is consistent in patients with 
or without concomitant amiodarone therapy.
 
